(CercleFinance.com) – Theradiag reported on Monday a turnover growth of 14.3% for its first quarter, mainly thanks to the strong growth of its in vitro diagnostics activity.
Over the first six months of the year, the company says it achieved a turnover of 6.3 million euros, against 5.5 million during the first half of 2021.
Its key ‘Theranostics’ division – which notably offers individualized therapeutic monitoring for patients undergoing biotherapies – recorded an increase in turnover of 9.3% to more than three million euros.
The in vitro diagnostics (IVD) activity posted growth of 19.3% to more than 3.2 million euros, supported by sales of diagnostic instruments, particularly in the veterinary sector.
As of June 30, the net available cash of the company based in Seine-et-Marne amounted to six million euros, compared to 7.1 million euros at the end of 2021.
Listed on the Paris Stock Exchange, Theradiag shares rose 2.5% on Monday morning following this publication.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
